Credit Suisse AG Has $1.37 Million Stock Position in Silk Road Medical, Inc (NASDAQ:SILK)

Credit Suisse AG lifted its holdings in shares of Silk Road Medical, Inc (NASDAQ:SILK – Get Rating) by 20.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 30,348 shares of the company’s stock after purchasing an additional 5,095 shares during the period. Credit Suisse AG owned 0.09% of Silk Road Medical worth $1,366,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Raymond James & Associates grew its position in shares of Silk Road Medical by 23.0% in the 1st quarter. Raymond James & Associates now owns 17,672 shares of the company’s stock valued at $730,000 after buying an additional 3,304 shares during the last quarter. US Bancorp DE boosted its holdings in Silk Road Medical by 41.3% in the first quarter. US Bancorp DE now owns 1,673 shares of the company’s stock valued at $69,000 after acquiring an additional 489 shares during the last quarter. MetLife Investment Management LLC increased its position in Silk Road Medical by 63.3% during the 1st quarter. MetLife Investment Management LLC now owns 18,697 shares of the company’s stock valued at $772,000 after purchasing an additional 7,246 shares during the period. Rhumbline Advisers raised its holdings in Silk Road Medical by 4.7% during the 1st quarter. Rhumbline Advisers now owns 35,607 shares of the company’s stock worth $1,470,000 after purchasing an additional 1,584 shares during the last quarter. Finally, BlackRock Inc. lifted its position in shares of Silk Road Medical by 1.2% in the 1st quarter. BlackRock Inc. now owns 2,556,071 shares of the company’s stock worth $105,542,000 after purchasing an additional 29,112 shares during the period. Institutional investors own 96.43% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Citigroup increased their price objective on shares of Silk Road Medical to $38.00 in a research report on Tuesday, November 15th. Argus boosted their price target on shares of Silk Road Medical from $60.00 to $70.00 in a research note on Monday, January 9th. Wolfe Research downgraded Silk Road Medical from an “outperform” rating to a “peer perform” rating in a research note on Tuesday, February 7th. Finally, Bank of America assumed coverage on shares of Silk Road Medical in a research report on Tuesday, November 22nd. They set a “buy” rating and a $60.00 price target on the stock.

Silk Road Medical Stock Performance

Shares of SILK opened at $46.47 on Thursday. Silk Road Medical, Inc has a 52 week low of $27.30 and a 52 week high of $58.04. The business’s 50 day moving average price is $52.22 and its 200-day moving average price is $48.60. The stock has a market cap of $1.79 billion, a P/E ratio of -29.98 and a beta of 1.22. The company has a quick ratio of 9.62, a current ratio of 10.41 and a debt-to-equity ratio of 0.46.

Silk Road Medical (NASDAQ:SILK – Get Rating) last issued its quarterly earnings results on Tuesday, February 28th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03. Silk Road Medical had a negative return on equity of 63.30% and a negative net margin of 39.81%. The business had revenue of $40.07 million during the quarter, compared to analysts’ expectations of $37.35 million. During the same quarter in the prior year, the business posted ($0.42) earnings per share. The business’s quarterly revenue was up 41.8% on a year-over-year basis. Equities research analysts anticipate that Silk Road Medical, Inc will post -1.51 earnings per share for the current fiscal year.

Insider Transactions at Silk Road Medical

In other Silk Road Medical news, CEO Erica J. Rogers sold 18,043 shares of the business’s stock in a transaction on Friday, March 3rd. The shares were sold at an average price of $47.10, for a total transaction of $849,825.30. Following the transaction, the chief executive officer now owns 269,132 shares in the company, valued at $12,676,117.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Silk Road Medical news, CFO Lucas W. Buchanan sold 9,918 shares of the business’s stock in a transaction that occurred on Friday, March 3rd. The stock was sold at an average price of $47.11, for a total transaction of $467,236.98. Following the completion of the transaction, the chief financial officer now owns 205,575 shares in the company, valued at $9,684,638.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Erica J. Rogers sold 18,043 shares of the company’s stock in a transaction that occurred on Friday, March 3rd. The shares were sold at an average price of $47.10, for a total value of $849,825.30. Following the transaction, the chief executive officer now directly owns 269,132 shares in the company, valued at approximately $12,676,117.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 272,328 shares of company stock worth $14,463,738. 7.66% of the stock is currently owned by company insiders.

Silk Road Medical Profile

(Get Rating)

Silk Road Medical, Inc develops and manufactures medical devices to treat neurovascular diseases. Its products include ENROUTE transcarotid neuroprotection system, ENROUTE transcarotid stent system, and ENROUTE transcarotid peripheral access kit. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.